10-May-2024
No headlines found.
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
PRNewswire (Mon, 6-May 7:00 AM ET)
PRNewswire (Thu, 25-Apr 7:00 AM ET)
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
PRNewswire (Wed, 10-Apr 7:00 AM ET)
Compugen to Participate in Two Upcoming Investor Conferences
PRNewswire (Wed, 3-Apr 7:00 AM ET)
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
PRNewswire (Mon, 11-Mar 7:00 AM ET)
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
PRNewswire (Wed, 6-Mar 7:00 AM ET)
Compugen Reports Fourth Quarter and Full Year 2023 Results
PRNewswire (Tue, 5-Mar 7:00 AM ET)
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
PRNewswire (Mon, 26-Feb 7:00 AM ET)
Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024
PRNewswire (Tue, 20-Feb 7:00 AM ET)
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
PRNewswire (Thu, 15-Feb 7:00 AM ET)
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
Compugen Ltd. - trades on the NASDAQ stock market under the symbol CGEN.
As of May 10, 2024, CGEN stock price declined to $2.01 with 271,779 million shares trading.
CGEN has a beta of 2.36, meaning it tends to be more sensitive to market movements. CGEN has a correlation of 0.07 to the broad based SPY ETF.
CGEN has a market cap of $177.54 million. This is considered a Micro Cap stock.
Last quarter Compugen Ltd. - reported $33 million in Revenue and $.11 earnings per share. This beat revenue expectation by $13 million and missed earnings estimates by -$.12.
In the last 3 years, CGEN stock traded as high as $9.20 and as low as $.51.
The top ETF exchange traded funds that CGEN belongs to (by Net Assets): SPDW, GWX.
CGEN has outperformed the market in the last year with a price return of +168.0% while the SPY ETF gained +27.8%. However, in the short term, CGEN had mixed performance relative to the market. It has underperformed in the last 3 months, returning -6.1% vs +4.2% return in SPY. But in the last 2 weeks, CGEN shares have fared better than the market returning +4.7% compared to SPY +2.5%.
CGEN support price is $2.00 and resistance is $2.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGEN stock will trade within this expected range on the day.